Last updated: 2026-09-06 09:43:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Quince Therapeutics, Inc. (QNCX) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $31.34, with a market capitalization of $32.70M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $15.10 to $909.98. This page covers its latest market performance, valuation, price trends and company information.
$32.70M | |
$30.53 | |
$909.98 | |
$15.10 | |
$30.55 | |
37.47K | |
-- | |
-- | |
$909.98 | |
$15.10 | |
-- | |
-- |
Quince Therapeutics, Inc. (QNCX) last closed at $30.55 as of 2026-09-04 23:44:00, unchanged from the previous close of $30.55.
During the latest regular trading session, QNCX traded between $15.10 and $909.98, with a volume of 37.47K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Quince Therapeutics, Inc. (QNCX) moved from $34.04 to $31.34, representing a decline of 7.93% ($2.70).
The stock traded between $29.48 and $33.45 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 22.67 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 1.8%
QNCX is currently trading at $31.34, placing it 1.8% of the way from its 52-week low of $15.10 to its 52-week high of $909.98. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 38 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Quince Therapeutics, Inc. (QNCX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.